Unconjugated antibodies for cancer therapy: Lessons from the clinic

Cancer Treatment Reviews

Volumn 23, Issue 5-6, 1997, Pages 305-319

  Ward, R L ^a,c   Hawkins, N J ^b   Smith, G M ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CRC for Biopharmaceutical Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EDRECOLOMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER 2; RITUXIMAB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG FEVER; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; RASH; REVIEW; SKIN DISEASE; VOMITING;

EID: 0031474496     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90030-X     Document Type: Article

References (79)

1. Clark, M. (1993) Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Academic Titles, Oxford, UK.
2. Pietersz, G. A., McKenzie, I. F. (1992) Antibody conjugates for the treatment of cancer, Immunol. Rev. 129: 57-80.
3. Isaacs, J. (1990) The antiglobulin response to therapeutic antibodies. Sem. Immunol. 2: 449-456.
4. Morrison, S. L., Johnson, M. J., Herzenberg, L. A. et al. (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 81: 6851-6855.
5. Jones, P. T., Dear, P. J., Foote, J. et al. (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525.
6. Riechmann, L., Clark, M, Waldmann, H. et al. (1988) Reshaping human antibodies for therapy. Nature. 332: 323-327.
7. LoBuglio, A. F., Wheeler, R. H., Trang, J. et al. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA. 86: 4220-4224.
8. Vitetta, E. S., Uhr, J. W. (1994) Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res. 54: 5301-5309.
9. Waldmann, T. A., Goldman, C. K., Bongiovanni, K. F. et al. (1988) Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805-1816.
10. Evans, S. S., Lee, D. B., Han, T. et al. (1990) Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. Blood 73: 2583-2593.
11. Green, D. R., Bissonnette, R. P., Glynn, J. M. et al. (1992) Activation-induced apoptosis in lymphoid systems. Sem Immunol. 4: 379-388.
12. Waddick, K. G., Chae, H. P., Tuel-Ahlgren, L. et al. (1993) Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. Radiation Res. 136: 313-319.
13. Hale, G., Clark, M., Waldmann, H. (1985) Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J. Immunol. 134: 3056-3061.
14. Dillman, R. O. (1994) Monoclonal antibodies as tumour therapy - clinical evidence in favour of their potential usefulness. Clin Immunother. 2: 206-219.
15. Fagerberg, J, Mellstedt, A. (1995) Anti-idiotypes and cancer. Cancer J. 8: 181-184.
16. Herlyn, D., Ross, A. H., Koprowski, H. (1986) Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 232: 100-102.
17. Fagerberg, J., Ragnhammar, P., Liljefors, M. et al. (1996) Humoral anti-idiotypic and anti-antiidiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother. 42: 81-87.
18. Herlyn, D., Wettendorff, M., Schmoll, E. et al. (1987) Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 84: 8055-8059.
19. Mittelman, A., Chen, Z. J., Yang, H. et al. (1992) Human high molecular weight melanomaassociated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89: 466-470.
20. Riethmuller, G., Schneidergadicke, E., Schlimok, G. et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343: 1177-1183.
21. Maloney, D. G., Liles, T. M., Czerwinski, D. K. et al. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466.
22. Baselga, J., Tripathy, D., Mendelsohn, J. et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 (HER2) monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J Clin Oncol. 14: 737-744.
23. McKnight, M. E., Prather, K., Koda, K. et al. (1991) Use of severe combined immunodeficient (SCID) mice to produce human hybridoma ascites. Hum Antibodies Hybridomas 2: 190-193.
24. Pistillo, M. P., Sguerso, V., Ferrara, G. B. (1992) High yields of anti-HLA human monoclonal antibodies can be provided by SCID mice. Hum Immunol. 35: 256-259.
25. Genzyme Transgenics web site: http://www.genzyme.com/ir/gztc/transgen.htm
26. Birch, B. J., Flatman, S., Vranch, S. (1995) The production of monoclonal antibodies. New York: Wiley-Liss.
27. Bebbington, C. (1994) Expression of antibody genes in mammalian cells. In: Zola, H. ed. Monoclonal Antibodies: The Second Generation. BIOS Scientific Publishers, Oxford, UK.
28. Janne, J., Hyttinen, J. M., Peura, T. et al. (1994) Transgenic bioreactors. Int J Biochem. 26: 859-870.
29. Velander, W. H., Lubon, H., Drohan, W. N. (1997) Transgenic livestock as drug factories. Scientif am. 276: 54-58.
30. McLaughlin, P., Cabanillas, F., Grillo-Lopez, A. J. et al. (1996) IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 88: 90a.
31. Carter, P., Presta, L., Gorman, C. M. et al. (1992) Humanization of an anti-P185HER-2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289.
32. Reff, M. E., Carner, K., Chambers, K. S. et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
33. Herlyn, M., Steplewski, Z., Herlyn, D. et al. (1986) CO 17-1A and related monoclonal antibodies: their production and characterization. Hybridoma 5: S3-10.
34. Gottlinger, H. G., Funke, I., Johnson, J. P. et al. (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies, Int J Cancer 38: 47-53.
35. Szala, S., Froehlich, M., Scollon, M. et al. (1990) Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci USA 87: 3542-3546.
36. Earp, H. S., Dawson, T. L., Li, X. et al. (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 35: 115-132.
37. Beerli, R. R., Graus-Porta, D., Woods-Cook, K. et al. (1995) Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol. 15: 6496-6505.
38. Sarup, J. C., Johnson, R. M., King, K. L et al. (1991) Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Reg. 1: 72-82.
39. Ledbetter, J. A., Clark, E. A. (1986) Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets. Hum Immunol. 15: 30-43.
40. Koprowski, H., Steplewski, Z., Mitchell, K. et al. (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Som Cell Genet. 5: 957-971.
41. Einfeld, D. A., Brown, J. P., Valentine, M. A. et al. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J7: 711-717.
42. Holz, E., Gruber R, Riethmuller, G. (1996) Monoclonal antibodies in cancer therapy - new perspective after the colorectal carcinoma trial. Clin Immunother. 5: 214-222.
43. Mellstedt, H., Frodin, J. E., Masucci, G. et al. (1991) The therappeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol. 18: 462-477.
44. Thorban, S., Roder, J. D., Nekarda, H. et al. (1996) Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst. 88: 1222-1227.
45. Moertel, C. G., Fleming, T. R., Macdonald, J. S. et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Int Med. 122: 321-326.
46. Riethmuller, G. (1996) Update on monoclonal antibody 17-1A adjuvant therapy. 32nd Annual Meeting of ASCO 18-21 May.
47. Impact. (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: 939-944.
48. Natali, P. G., Nicotra, M. R., Bigotti, A. et al. (1990) Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues, Int J Cancer 45: 457-461.
49. Slamon, D. J., Godolphin, W., Jones, L. A. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
50. Bacus, S. S., Stancovski, I., Huberman, E. et al. (1992) Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52: 2580-2589.
51. Hurwitz, E., Stancovski, I., Sela, M. et al. (1995) Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 92: 3353-3357.
52. Klapper, L. N., Vaisman, N., Hurwitz, E. et al (1997) A subclass of tumor-inhibitory monoclonal antibodies to erbB-2/HER-2 blocks crosstalk with growth factor receptors. Oncogene 14: 2099-2109.
53. Kardinal C. Chemotherapy of breast cancer. The chemotherapy source book 1992; Michael Perry ed: 948-988.
54. Hancock, M. C., Langton, B. C., Chan, T. et al. (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51: 4575-4580.
55. Pietras, R. J., Fendly, B. M., Chazin, V. R. et al. (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-1838.
56. Twaddell, T. Clinical experience with rhuMAb HER2 in metastatic breast cancer. Antibody engineering, new technology, applications and commercialization. 1995; Dec 4-6th, La Jolla, California.
57. Maloney, D. G., Bodkin, K., Grillo-Lopez, A. J. et al. (1994) Final report of a Phase II trial in relapsed non-Hodgkin's lymphoma. Blood 84: 169a.
58. Maloney, D. G., Grillo-Lopez, A. J., Bodkin, K. et al. (1995) IDEC-C2B8 anti-CD20 antibody: results of long-term follow-up of relapsed NHL phase II trial patients. Blood 86: 54a.
59. McLaughlin, P., Grillo-Lopez, A. J., Czuczman, M. et al. (1997) IDEC-C2B8 (rituximab): clinical activity in clinically chemoresistant low-grade or follicular lymphoma (LG/F NHL) and in patients relapsing after anthracycline therapy or ABMT. Proc. Am Soc Clin Oncol. 16: 16a.
60. Czuczman, M., Grillo-Lopez, A. J., White, C. A. et al. (1996) IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: clinical and BCL-2 (PCR) final results. Stood 88: 453a.
61. Lister, T. A., Armitage, J. O. Non-Hodgkin's Lymphoma. (1995) In: Abeloff MD, A. J., Lichter, A. S., Niederhuber, J. E., ed, Clinical Oncology. New York: Churchill Livingstone, pp 2109-2147.
62. Pai, L. H., Bookman, M. A., Ozols, R. F. et al. (1991) Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer [see comments]. J Clin Oncol. 9: 2095-2103.
63. Mach, J. P., Chatal, J. F., Lumbroso, J. D. et al. (1983) Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res. 43: 5593-5600.
64. Meredith, R. F., LoBuglio, A. F., Plott, W. E. et al. (1991) Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody. J Nuc Med. 32: 1162-1168.
65. Langmuir, V. K., Mendonca, H. L., Wood, D. V. (1992) Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res. 52: 4728-4734.
66. Robinson, R. R., Chartier, J, Jr., Change, C. P. et al. (1991) Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum Antibodies Hybridomas 2: 84-93.
67. Riethmuller, G., Johnson, J. P. (1992) Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol. 4: 647-655.
68. Frodin, J. E., Faxas, M. E., Hagstrom, B. et al. (1991) Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1a (ab1). Relation to the clinical outcome - an important antitumoral effector function? Hybridoma 10: 421-431.
69. Herlyn, D., Sears, H., lliopoulos, D. et al. (1986) Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 5: S51-58.
70. Fagerberg, J., Frodin, J. E., Wigzell, H. et al. (1993) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (Ab(D).1. May induction of ab(1)-reactive t-cells and anti-anti-idiotypic antibodies (Ab(3)) lead to tumor regression after Mab therapy. Cancer Immunol Immunother. 37: 264-270.
71. Fagerberg, J., Frodin, J. E., Ragnhammar, P. et al. (1994) Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (Ab(D).2. Is induction of antiidiotype reactive t cells (T-3) of importance for tumor response to Mab therapy. Cancer Immunol Immunother. 38: 149-159.
72. Shawver, L. K., Mann, E., Elliger, S. S. et al. (1994) Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res. 54: 1367-1373.
73. Scott, G. K., Robles, R., Park, J. W. et al. (1993) A truncated intracellular HER2-neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cel Biol. 13: 2247-2257.
74. Baselga, J., Norton, L., Coplan, K. et al. (1994) Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res. 35: 380.
75. Anderson, K. C., Bates, M. P., Slaughenhoupt, B. L et al. (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63: 1424-1433.
76. Tedder, T. F., Engel, P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15: 450-454.
77. Anonymous: Points to consider in the manufacture and testing of monoclonal antibodies for human use.: US Department of Health and Human Services, Food and Drug Administration, Centre for Biologics Evaluation and Research, 1997.
78. Khazaeli, M. B., Saleh, M. N., Wheeler, R. H. et al. (1988) Phase I trail of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 80: 937-942.
79. Frodin, J. E., Lefvert, A. K., Mellstedt, H. (1990) Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res. 50: 4866-4871.